Bio-Rad Laboratories anti-vedolizumab antibodies

Vedolizumab (Entyvio) is a monoclonal antibody that is used to treat ulcerative colitis (inflammatory bowel disease) and Crohn’s disease. Bio-Rad’s anti-vedolizumab antibodies, which support research into the treatment of these diseases, include four recombinant monoclonal anti-idiotypic antibodies that are highly specific for the humanised IgG1 kappa antibody drug vedolizumab, and are suitable for development of bioanalytical and patient monitoring assays.

The recombinant monoclonal anti-vedolizumab antibodies are generated using the Human Combinatorial Antibody Library (HuCAL) and CysDisplay, a proprietary method of phage display, resulting in targeted reagents. The paratope-specific antibodies inhibit the binding of vedolizumab to its target, alpha4beta7 integrin, which makes them suitable for development of a pharmacokinetic bridging ELISA to monitor free drug levels or as reference standards in anti-drug antibody assays. The recombinant production method ensures a consistent and secure supply.

The anti-vedolizumab antibodies are approved for in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development and patient monitoring.